13.00Open13.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover305.58%IV-9.57%PremiumJan 17, 2025Expiry Date13.83Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8352Delta0.0408Gamma0.61Leverage Ratio-0.0362Theta-0.0084Rho-0.51Eff Leverage0.0050Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet